2. Abstract
Single-arm trials supplemented with external comparator arm(s) (ECA) derived from real-world data are sometimes used when randomized trials are infeasible. However, due to data sharing restrictions, privacy/security concerns, or for logistical reasons, patient-level real-world data may not be available to researchers for analysis. Instead, it may be possible to use generative models to construct synthetic data from the real-world dataset that can then be freely shared with researchers. Although the use of generative models and synthetic data is gaining prominence, the extent to which a synthetic data ECA can replace original data while preserving patient privacy in small samples is unclear.
Objective To compare the efficacy of nivolumab + ipilimumab combination therapy (“experimental arm”) versus nivolumab monotherapy (“control arm”) in patients with metastatic non-small cell lung cancer (mNSCLC) using real-world data from two real-world databases (“original ECA”), and synthetic data versions of these datasets (“synthetic ECA”), with the aim of validating synthetic data for use in ECA analysis.
Study design Non-randomized analyses of treatment efficacy comparing the experimental arm to the (i) original ECA and (ii) synthetic ECA, with baseline confounding adjustment.
Data sources The experimental arm is from the Lung-MAP no-match substudy S1400I (NCT02785952) provided by National Clinical Trials Network (NCTN) in the United States. The real-world data source for the ECA is data from population-based oncology data from the Canadian province of Alberta, and from Nordic countries in Europe, specifically Denmark and Norway.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Health Research Ethics Board of Alberta (HREBA) provided ethics approval (approval number HREBA.CC-24-0173). Ethics approval was in place for use of Nordic data for the content of this study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Research question & Objectives
To compare the efficacy of
Nivolumab + ipilimumab combination therapy versus
Nivolumab monotherapy
in patients with metastatic non-small cell lung cancer using real-world data and synthetic data derived from the same, with the aim of validating synthetic data for use in external control arm analysis.
Contributors
Primary investigator contact information:
Alind Gupta (alind.gupta{at}utoronto.ca)
Contributor names:
Luke Segars
David Singletary
Paul Arora
Johan Liseth Hansen
Kirk Geale
Anmol Arora
Manuel Gomes
Sreeram Ramagopalan
Winson Cheung
Study registration
Site: n/a
Identifier: n/a
Sponsor
Organization: n/a
Contact: n/a
Conflict of interest
None
Data Availability
All data produced in the present study are available upon request to the relevant coauthors.